Pancreatic Cancer Research

ResearcherCharles UniversityActive in the last 2 years

R Gürlich

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8432-2266; OpenAlex author ID A5018609926, A5069723334. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper

Papers 12

  1. Pancreatic surgery at the University Hospital Kralovske Vinohrady: 10-year review with a survival analysis for pancreatic ductal adenocarcinoma. Co-author DOI 10.33699/pis.2024.103.4.132-137↗
  2. Early-onset pancreatic cancer: A national cancer registry study from the Czech Republic and review of the literature. Last author DOI 10.1002/jhbp.1359↗
  3. Segmental Versus Partial Portomesenteric Resection in Pancreatectomy for Pancreatic Cancer. First author DOI 10.1016/j.jss.2023.03.002↗
  4. Expression of Selected miRNAs in Normal and Cancer-Associated Fibroblasts and in BxPc3 and MIA PaCa-2 Cell Lines of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms24043617↗
  5. Introducing in vivo pancreatic cancer models for the study of new therapeutic regimens Co-author DOI 10.33699/pis.2022.101.12.584-592↗
  6. Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cance… Co-author DOI 10.21873/cgp.20254↗
  7. Circulating Tumor Cells, Circulating Tumor DNA and Other Blood-based Prognostic Scores in Pancreatic Ductal Adenocarcinoma - Mini-Review. Co-author DOI 10.21873/invivo.12229↗
  8. Expression of selected microRNAs in pancreatic ductal adenocarcinoma: is there a relation to tumor morphology, progression and patient's outcome? First author DOI 10.4149/neo_2020_200123n87↗
  9. Expression of selected MicroRNAs in pancreatic ductal adenocarcinoma in relation to tumor progression and patient’s outcome. Co-author DOI 10.21203/rs.2.18344/v1↗
  10. Tumor grade as significant prognostic factor in pancreatic cancer: validation of a novel TNMG staging system. Co-author DOI 10.4149/neo_2018_171012n650↗
  11. Heme oxygenase is not involved in the anti-proliferative effects of statins on pancreatic cancer cells. Co-author DOI 10.1186/s12885-016-2343-9↗
  12. [Current status regarding surgical treatment of pancreatic cancer in the Czech Republic]. Co-author PMID 27226268↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam Whitley · 3 shared papers, 2023–2024 · strength 0.72
  2. Árpád Szabó · 5 shared papers, 2019–2022 · strength 0.64
  3. Martin Oliverius · 3 shared papers, 2021–2024 · strength 0.62
  4. Václav Mandys · 3 shared papers, 2019–2023 · strength 0.41
  5. Alexey Popov · 3 shared papers, 2019–2023 · strength 0.41
  6. Renata Soumarová · 3 shared papers, 2019–2021 · strength 0.39
  7. Marián Liberko · 3 shared papers, 2019–2021 · strength 0.39
  8. Pavol Szabó · 2 shared papers, 2021–2023 · strength 0.28
  9. David Girsa · 1 shared paper, 2023 · strength 0.22
  10. Kateřina Lawrie · 1 shared paper, 2023 · strength 0.22
  11. Peter Baláž · 1 shared paper, 2023 · strength 0.22
  12. Lukáš Havlůj · 1 shared paper, 2023 · strength 0.22
  13. Tomas Sychra · 1 shared paper, 2022 · strength 0.15
  14. Pavel Souček · 1 shared paper, 2022 · strength 0.15
  15. Jan Hlavsa · 2 shared papers, 2016–2018 · strength 0.13
  16. Martin Loveček · 2 shared papers, 2016–2018 · strength 0.13
  17. Stepan Novak · 1 shared paper, 2021 · strength 0.10
  18. Josef Dvořák · 1 shared paper, 2021 · strength 0.10
  19. Matúš Čoma · 1 shared paper, 2021 · strength 0.10
  20. Pavel Záruba · 1 shared paper, 2018 · strength 0.08
  21. Zdeněk Kala · 1 shared paper, 2018 · strength 0.08
  22. Jiřı́ Neužil · 1 shared paper, 2016 · strength 0.06
  23. Tomáš Ruml · 1 shared paper, 2016 · strength 0.06
  24. Štěpána Boukalová · 1 shared paper, 2016 · strength 0.06
  25. Katerina Hadrava Vanova · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.